Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation.
COVID-19
Chemotherapy
Immunotherapy
Lung cancer
SARS-CoV-2
Vaccine
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
20
09
2021
revised:
30
10
2021
accepted:
01
11
2021
pubmed:
15
11
2021
medline:
29
1
2022
entrez:
14
11
2021
Statut:
ppublish
Résumé
Patients with lung cancer are especially vulnerable to coronavirus disease 2019 (COVID-19) with a greater than sevenfold higher rate of becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19, a greater than threefold higher hospitalization rate with high complication rates, and an estimated case fatality rate of more than 30%. The reasons for the increased vulnerability are not known. In addition, beyond the direct impact of the pandemic on morbidity and mortality among patients with lung cancer, COVID-19, with its disruption of patient care, has also resulted in substantial impact on lung cancer screening and treatment/management.COVID-19 vaccines are safe and effective in people with lung cancer. On the basis of the available data, patients with lung cancer should continue their course of cancer treatment and get vaccinated against the SARS-CoV-2 virus. For unknown reasons, some patients with lung cancer mount poor antibody responses to vaccination. Thus, boosting vaccination seems urgently indicated in this subgroup of vulnerable patients with lung cancer. Nevertheless, many unanswered questions regarding vaccination in this population remain, including the magnitude, quality, and duration of antibody response and the role of innate and acquired cellular immunities for clinical protection. Additional important knowledge gaps also remain, including the following: how can we best protect patients with lung cancer from developing COVID-19, including managing care in patient with lung cancer and the home environment of patients with lung cancer; are there clinical/treatment demographics and tumor molecular demographics that affect severity of COVID-19 disease in patients with lung cancer; does anticancer treatment affect antibody production and protection; does SARS-CoV-2 infection affect the development/progression of lung cancer; and are special measures and vaccine strategies needed for patients with lung cancer as viral variants of concern emerge.
Identifiants
pubmed: 34774792
pii: S1556-0864(21)03309-8
doi: 10.1016/j.jtho.2021.11.001
pmc: PMC8579698
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
214-227Subventions
Organisme : NCI NIH HHS
ID : U54 CA260560
Pays : United States
Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA163072
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA163056
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA098131
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA068485
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA236733
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93019C00051
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA213274
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Informations de copyright
Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Références
J Clin Oncol. 2021 Jan 10;39(2):155-169
pubmed: 33290128
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Nat Rev Cancer. 2009 Apr;9(4):239-52
pubmed: 19279573
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
Transl Lung Cancer Res. 2020 Aug;9(4):1516-1527
pubmed: 32953523
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Radiol Imaging Cancer. 2020 Apr 23;2(3):e204013
pubmed: 33778716
Lancet. 2021 Jun 26;397(10293):2461-2462
pubmed: 34139198
Cancer Discov. 2020 Jul 31;:
pubmed: 32737082
JAMA Oncol. 2021 Feb 1;7(2):304-306
pubmed: 33331862
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
Cancer Discov. 2021 Oct;11(10):2430-2435
pubmed: 34475136
JAMA Oncol. 2021 Oct 1;7(10):1507-1513
pubmed: 34236381
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Lancet Oncol. 2021 Dec;22(12):1681-1691
pubmed: 34767759
Crit Rev Oncol Hematol. 2021 Jul;163:103365
pubmed: 34052423
Ann Oncol. 2021 Jun;32(6):787-800
pubmed: 33746047
Chest. 2022 Feb;161(2):586-589
pubmed: 34298006
JCO Glob Oncol. 2020 Sep;6:1428-1438
pubmed: 32986516
J Am Coll Surg. 2021 Apr;232(4):600-605
pubmed: 33346080
Front Oncol. 2017 Sep 08;7:195
pubmed: 28944214
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Nature. 2021 Aug;596(7870):17-18
pubmed: 34321643
Int J Cancer. 2020 Dec 1;147(11):3264-3266
pubmed: 32525565
Ann Oncol. 2020 Oct;31(10):1386-1396
pubmed: 32561401
Nat Med. 2021 Nov;27(11):2002-2011
pubmed: 34594036
JAMA Oncol. 2021 Aug 1;7(8):1133-1140
pubmed: 34047765
Microorganisms. 2021 Aug 09;9(8):
pubmed: 34442770
Cancer Discov. 2020 Oct;10(10):1514-1527
pubmed: 32699031
J Thorac Oncol. 2020 Aug;15(8):e141-e142
pubmed: 32387713
J Thorac Oncol. 2022 Feb;17(2):239-251
pubmed: 34798306
Cancers (Basel). 2021 Jun 09;13(12):
pubmed: 34207878
JAMA Netw Open. 2020 Aug 3;3(8):e2017267
pubmed: 32749465
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
J Transl Med. 2020 Dec 3;18(1):457
pubmed: 33272291
Nat Med. 2021 Jul;27(7):1147-1148
pubmed: 34239135
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Lancet Oncol. 2021 May;22(5):581-583
pubmed: 33812495
Curr Cancer Drug Targets. 2021 Jul 5;21(5):428-442
pubmed: 33292131
Cancer Discov. 2020 Aug;10(8):1121-1128
pubmed: 32398243
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Thorac Cancer. 2020 Oct;11(10):2983-2986
pubmed: 32790028
Cancer Invest. 2021 Mar;39(3):205-213
pubmed: 33534645
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
JCO Oncol Pract. 2020 Jul;16(7):417-421
pubmed: 32396491
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
J Pathol. 2021 Jan;253(1):17-30
pubmed: 32991738
Clin Lung Cancer. 2020 Nov;21(6):568-570
pubmed: 32928688
Crit Rev Oncol Hematol. 2019 Oct;142:26-34
pubmed: 31352168
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Monaldi Arch Chest Dis. 2020 Jul 14;90(3):
pubmed: 32664711
JAMA Oncol. 2021 Nov 1;7(11):1716-1718
pubmed: 34379092
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
Br J Cancer. 2021 Sep;125(6):798-805
pubmed: 34211120
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
JAMA Oncol. 2021 Jun 1;7(6):878-884
pubmed: 33914015
Br J Cancer. 2021 Apr;124(8):1353-1356
pubmed: 33526866
Ann Surg Oncol. 2021 Nov;28(12):7311-7316
pubmed: 34236550
Front Cell Dev Biol. 2021 Apr 27;9:578825
pubmed: 33987176
Nat Rev Cancer. 2009 Apr;9(4):265-73
pubmed: 19262571
JAMA Netw Open. 2020 Jun 1;3(6):e2010651
pubmed: 32478845
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
BMC Pulm Med. 2019 Aug 14;19(1):149
pubmed: 31412851
Sci Immunol. 2021 Mar 10;6(57):
pubmed: 33692097
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
BMC Cancer. 2020 Oct 29;20(1):1040
pubmed: 33121456
Expert Rev Respir Med. 2021 Jun;15(6):791-803
pubmed: 33902377
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2
pubmed: 34133951
Eur J Cancer. 2021 Sep;154:66-72
pubmed: 34243079
Lancet Oncol. 2021 Jan;22(1):66-73
pubmed: 33253639